Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | COO | December 14, 2017 | December 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date December 14, 2017 · Filed December 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2027-12-14 | Direct | 20,000 |
Reported balance
After 2017-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-12-14 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% accelerated vesting on change of control. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2027-12-14 | Direct | 60,000 |
Reported balance
After 2017-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-14 · Grant · Acquired 60,000 · Balance 60,000 F1: 100% accelerated vesting on change of control. F2: After twelve months from the Grant Date option vest 2.0833% monthly. All options vested 48 months from Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% accelerated vesting on change of control.
F2: After twelve months from the Grant Date option vest 2.0833% monthly. All options vested 48 months from Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2017 Filed Dec 18, 2017 21:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000318306-17-000002 · primary_doc.xml · derivative · entry 2 Jeffrey B Davis · CIK 0001349083 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common stock · 60,000 shares Expires 2027-12-14 F1 · shares: 100% accelerated vesting on change of control. F2 · derivative.exercise_date: After twelve months from the Grant Date option vest 2.0833% monthly. All options vested 48 months from Grant Date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000318306-17-000002 · primary_doc.xml · derivative · entry 1 Jeffrey B Davis · CIK 0001349083 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common stock · 20,000 shares Expires 2027-12-14 F1 · shares: 100% accelerated vesting on change of control. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 00:48 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 112,500 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000318306-16-000051 · primary_doc.xml · derivative · entry 2 Jeffrey B Davis · CIK 0001349083 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 112,500 shares Expires 2026-12-13 F1 · shares: 100% accelerated vesting on change of control. F2 · derivative.exercise_date: After twelve months from Grant Date options vest 2.0833% monthly. All options vested 48 months from Grant Date. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 00:48 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000318306-16-000051 · primary_doc.xml · derivative · entry 1 Jeffrey B Davis · CIK 0001349083 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common stock · 37,500 shares Expires 2026-12-13 F1 · shares: 100% accelerated vesting on change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.